J. Goldman & Co’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.7M Buy
+268,081
New +$1.86M 0.03% 428

Other funds holding TRDA

J. Goldman & Co's TRDA Position: Q3 2026 in Review

J. Goldman & Co opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 268,081 shares worth $1.7M. The stake represents 0.03% of the portfolio and ranks #428 among its holdings.

132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • J. Goldman & Co held 268,081 shares of Entrada Therapeutics worth $1.7M as of Q3 2026.
  • Entrada Therapeutics was a new J. Goldman & Co position in Q3 2026.
  • Entrada Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q3 2026, its #428 holding.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on J. Goldman & Co's 13F filing for Q3 2026, filed 16 Nov 2026.